vs

Side-by-side financial comparison of ARTS WAY MANUFACTURING CO INC (ARTW) and Taysha Gene Therapies, Inc. (TSHA). Click either name above to swap in a different company.

Taysha Gene Therapies, Inc. is the larger business by last-quarter revenue ($5.5M vs $5.1M, roughly 1.1× ARTS WAY MANUFACTURING CO INC). ARTS WAY MANUFACTURING CO INC runs the higher net margin — -12.7% vs -507.8%, a 495.0% gap on every dollar of revenue. On growth, Taysha Gene Therapies, Inc. posted the faster year-over-year revenue change (171.3% vs -17.9%). Over the past eight quarters, Taysha Gene Therapies, Inc.'s revenue compounded faster (26.8% CAGR vs -5.9%).

Art's Way Manufacturing is an American producer of agricultural machinery, modular buildings and cutting tools under the brand names Art's Way, Art's Way Scientific and American Carbide Tool. The firm previously manufactured OEM feed blowers sold by Case New Holland.

Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company specializing in developing adeno-associated virus (AAV)-based gene therapies for rare monogenic central nervous system disorders with high unmet medical needs. Its core pipeline targets serious life-threatening neurological conditions, with primary operations and market focus across North America and European regions.

ARTW vs TSHA — Head-to-Head

Bigger by revenue
TSHA
TSHA
1.1× larger
TSHA
$5.5M
$5.1M
ARTW
Growing faster (revenue YoY)
TSHA
TSHA
+189.2% gap
TSHA
171.3%
-17.9%
ARTW
Higher net margin
ARTW
ARTW
495.0% more per $
ARTW
-12.7%
-507.8%
TSHA
Faster 2-yr revenue CAGR
TSHA
TSHA
Annualised
TSHA
26.8%
-5.9%
ARTW

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ARTW
ARTW
TSHA
TSHA
Revenue
$5.1M
$5.5M
Net Profit
$-645.5K
$-27.9M
Gross Margin
18.6%
Operating Margin
-11.2%
-516.0%
Net Margin
-12.7%
-507.8%
Revenue YoY
-17.9%
171.3%
Net Profit YoY
-177.6%
-48.3%
EPS (diluted)
$-0.13
$-0.08

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ARTW
ARTW
TSHA
TSHA
Q4 25
$5.1M
$5.5M
Q3 25
$6.4M
$0
Q2 25
$6.3M
$2.0M
Q1 25
$5.1M
$2.3M
Q4 24
$6.2M
$2.0M
Q3 24
$5.9M
$1.8M
Q2 24
$6.7M
$1.1M
Q1 24
$5.7M
$3.4M
Net Profit
ARTW
ARTW
TSHA
TSHA
Q4 25
$-645.5K
$-27.9M
Q3 25
$254.1K
$-32.7M
Q2 25
$1.5M
$-26.9M
Q1 25
$-55.8K
$-21.5M
Q4 24
$832.0K
$-18.8M
Q3 24
$-26.2K
$-25.5M
Q2 24
$-33.3K
$-20.9M
Q1 24
$-465.0K
$-24.1M
Gross Margin
ARTW
ARTW
TSHA
TSHA
Q4 25
18.6%
Q3 25
27.5%
Q2 25
32.5%
Q1 25
29.1%
Q4 24
36.1%
Q3 24
28.9%
Q2 24
28.3%
Q1 24
25.7%
Operating Margin
ARTW
ARTW
TSHA
TSHA
Q4 25
-11.2%
-516.0%
Q3 25
5.4%
Q2 25
8.1%
-1347.1%
Q1 25
0.0%
-930.5%
Q4 24
8.4%
-985.8%
Q3 24
2.6%
-1448.4%
Q2 24
2.5%
-1915.4%
Q1 24
-6.6%
-713.3%
Net Margin
ARTW
ARTW
TSHA
TSHA
Q4 25
-12.7%
-507.8%
Q3 25
4.0%
Q2 25
23.4%
-1353.6%
Q1 25
-1.1%
-935.2%
Q4 24
13.5%
-929.0%
Q3 24
-0.4%
-1427.5%
Q2 24
-0.5%
-1882.0%
Q1 24
-8.1%
-705.4%
EPS (diluted)
ARTW
ARTW
TSHA
TSHA
Q4 25
$-0.13
$-0.08
Q3 25
$0.05
$-0.09
Q2 25
$0.29
$-0.09
Q1 25
$-0.01
$-0.08
Q4 24
$0.17
$-0.07
Q3 24
$-0.01
$-0.10
Q2 24
$-0.01
$-0.09
Q1 24
$-0.09
$-0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ARTW
ARTW
TSHA
TSHA
Cash + ST InvestmentsLiquidity on hand
$4.8K
$319.8M
Total DebtLower is stronger
$2.5M
Stockholders' EquityBook value
$13.3M
$246.9M
Total Assets
$22.5M
$343.3M
Debt / EquityLower = less leverage
0.19×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ARTW
ARTW
TSHA
TSHA
Q4 25
$4.8K
$319.8M
Q3 25
$6.0K
$297.3M
Q2 25
$4.5K
$312.8M
Q1 25
$4.1K
$116.6M
Q4 24
$1.9K
$139.0M
Q3 24
$5.1K
$157.7M
Q2 24
$4.5K
$172.7M
Q1 24
$2.5K
$124.0M
Total Debt
ARTW
ARTW
TSHA
TSHA
Q4 25
$2.5M
Q3 25
Q2 25
Q1 25
Q4 24
$2.1M
Q3 24
$2.7M
Q2 24
$2.7M
Q1 24
$2.7M
Stockholders' Equity
ARTW
ARTW
TSHA
TSHA
Q4 25
$13.3M
$246.9M
Q3 25
$13.9M
$219.0M
Q2 25
$13.6M
$248.7M
Q1 25
$12.1M
$55.1M
Q4 24
$12.1M
$71.5M
Q3 24
$11.3M
$88.8M
Q2 24
$11.2M
$108.9M
Q1 24
$11.2M
$53.8M
Total Assets
ARTW
ARTW
TSHA
TSHA
Q4 25
$22.5M
$343.3M
Q3 25
$21.8M
$316.6M
Q2 25
$20.9M
$333.3M
Q1 25
$21.0M
$138.4M
Q4 24
$21.2M
$160.4M
Q3 24
$23.5M
$180.2M
Q2 24
$23.2M
$200.4M
Q1 24
$24.3M
$153.0M
Debt / Equity
ARTW
ARTW
TSHA
TSHA
Q4 25
0.19×
Q3 25
Q2 25
Q1 25
Q4 24
0.17×
Q3 24
0.24×
Q2 24
0.24×
Q1 24
0.24×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ARTW
ARTW
TSHA
TSHA
Operating Cash FlowLast quarter
$-889.2K
$-26.7M
Free Cash FlowOCF − Capex
$-1.0M
FCF MarginFCF / Revenue
-20.6%
Capex IntensityCapex / Revenue
3.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-1.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ARTW
ARTW
TSHA
TSHA
Q4 25
$-889.2K
$-26.7M
Q3 25
$-1.3M
$-24.2M
Q2 25
$1.4M
$-20.2M
Q1 25
$-101.8K
$-22.0M
Q4 24
$1.2M
$-18.3M
Q3 24
$282.4K
$-21.6M
Q2 24
$1.2M
$-21.5M
Q1 24
$-99.3K
$-19.8M
Free Cash Flow
ARTW
ARTW
TSHA
TSHA
Q4 25
$-1.0M
Q3 25
$-1.5M
$-24.3M
Q2 25
$1.2M
Q1 25
$-184.5K
Q4 24
$1.1M
$-18.3M
Q3 24
$180.5K
$-21.6M
Q2 24
$1.0M
$-21.7M
Q1 24
$-380.4K
$-19.9M
FCF Margin
ARTW
ARTW
TSHA
TSHA
Q4 25
-20.6%
Q3 25
-23.8%
Q2 25
19.3%
Q1 25
-3.6%
Q4 24
17.6%
-905.5%
Q3 24
3.1%
-1210.9%
Q2 24
15.1%
-1951.9%
Q1 24
-6.6%
-584.5%
Capex Intensity
ARTW
ARTW
TSHA
TSHA
Q4 25
3.0%
Q3 25
4.1%
Q2 25
2.1%
Q1 25
1.6%
Q4 24
1.8%
0.1%
Q3 24
1.7%
2.0%
Q2 24
3.4%
18.1%
Q1 24
4.9%
4.1%
Cash Conversion
ARTW
ARTW
TSHA
TSHA
Q4 25
Q3 25
-4.99×
Q2 25
0.91×
Q1 25
Q4 24
1.44×
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ARTW
ARTW

Agricultural Products$2.8M55%
Modular Buildings$2.2M44%

TSHA
TSHA

Segment breakdown not available.

Related Comparisons